Form 8-K Clovis Oncology, Inc. For: May 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
UPDATE: Clovis Oncology (CLVS) Misses Q1 EPS by 4c (Correction)
May 6, 2015 3:56 PM EDT(Updated - May 6, 2015 3:57 PM EDT)
Clovis Oncology (NASDAQ: CLVS) reported Q1 EPS of ($1.86), $0.04 worse than the analyst estimate of ($1.82). Revenue for the quarter came in at $0 , versus $13.6 million reported last year.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
... More


